John Robblee

Dr. Robblee brings over 15 years of development experience to the Chemistry, Manufacturing, and Controls (CMC) function at Carmine. At the exosome therapeutics company Codiak BioSciences, he led the Analytical Development team and played a leading Regulatory and CMC role in the successful IND/IMPD submissions of their first clinical products exoSTING and exoIL-12.

Before leading the Analytical Development team at the non-viral gene therapy company Generation Bio, he spent over a decade at Momenta Pharmaceuticals in the Analytical Research, Analytical Development, and CMC Regulatory groups on the analytical and regulatory framework for most of their biosimilar products, including biosimilar versions of Humira®, Orencia®, and Eylea®.

Dr. Robblee received his Ph.D. from the University of California, Berkeley in biophysical chemistry, and completed his postdoctoral training in the biochemistry department of the Massachusetts Institute of Technology.